---
title: "赛诺菲在第三季度业绩超预期后股价上涨，这主要得益于与 Regeneron 合作的 Dupixent 药物"
description: "赛诺菲的股价在公布超出预期的 2025 年第三季度业绩后小幅上涨，主要得益于其哮喘药物 Dupixent 的强劲销售，该药物创造了 42 亿欧元的收入，同比增长 26%。总销售额达到 124 亿欧元，超出分析师的预期。尽管疫苗销售下降了 8%，赛诺菲预计 2025 年将实现高单位数的销售增长和低双位数的每股收益增长。该公司正在与美国政策制定者就药品定价进行讨论，并扩大了其胰岛素节省计划，以改善获取"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262611409.md"
published_at: "2025-10-24T11:30:10.000Z"
---

# 赛诺菲在第三季度业绩超预期后股价上涨，这主要得益于与 Regeneron 合作的 Dupixent 药物

> 赛诺菲的股价在公布超出预期的 2025 年第三季度业绩后小幅上涨，主要得益于其哮喘药物 Dupixent 的强劲销售，该药物创造了 42 亿欧元的收入，同比增长 26%。总销售额达到 124 亿欧元，超出分析师的预期。尽管疫苗销售下降了 8%，赛诺菲预计 2025 年将实现高单位数的销售增长和低双位数的每股收益增长。该公司正在与美国政策制定者就药品定价进行讨论，并扩大了其胰岛素节省计划，以改善获取渠道

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, which is marketed in collaboration with Regeneron (NASDAQ:REGN). The Paris-based firm posted €12.4B ($14.4B) in sales and €2.91 ($3.38) of business earnin...

### Related Stocks

- [SNYNF.US - 赛诺菲](https://longbridge.com/zh-CN/quote/SNYNF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 4-Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant | Sanofi has ousted CEO Paul Hudson after a six-year tenure marked by a stalled turnaround and pressure on vaccine sales.  | [Link](https://longbridge.com/zh-CN/news/275748711.md) |
| 17:31 ETAtopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors \| DelveInsight | The atopic dermatitis market is projected to grow significantly by 2034, driven by the introduction of new therapies and | [Link](https://longbridge.com/zh-CN/news/276080710.md) |
| BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study | Shares of Upstream Biosurged 20% to $32.64 in premarket trading following positive results from a mid-stage study of its | [Link](https://longbridge.com/zh-CN/news/275596211.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/zh-CN/news/276017486.md) |
| Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns | Upstream Bio Inc. (NASDAQ:UPB) shares fell over 54% following mixed results from its asthma drug trials, despite analyst | [Link](https://longbridge.com/zh-CN/news/275923255.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。